This post was originally published on this site

[unable to retrieve full-text content]Shares of Emergent BioSolutions (NYSE: EBS) were falling 10.3% as of 11:45 a.m. EDT on Tuesday. The drop came after Johnson & Johnson announced that it had paused its late-stage study of coronavirus …